Hoth Therapeutics (HOTH) announced preclinical findings that highlight the potential of Glial Cell Line-Derived Neurotrophic Factor as a treatment for obesity. The study, conducted in GDNF-transgenic models, showed that GDNF significantly reduces fat accumulation, enhances metabolism, and improves insulin sensitivity, even under high-fat diet conditions.
"The data suggest that GDNF-based therapies could offer an entirely new approach to obesity treatment—one that activates the body's natural metabolic processes to burn excess fat efficiently," said Robb Knie, CEO Hoth Therapeutics.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.